Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endostatin for Radiation Pneumonia and Fibrosis
NCT03796364Phase 2Completed
- Sponsor
- Xinqiao Hospital
- Start
- Sep 2018
- Primary completion
- May 2020
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of endostar in radiation-induced lung injury (RILI), radiation pneumonitis (RP) and radiation fibrosis syndrome (RIF) (2 arms), sponsored by Xinqiao Hospital. Primary endpoint: Recrudescence Rate of Radiation Pneumonitis at 12 weeks. Started Sep 2018; status: completed.
02
Drugs
endostar
03
Conditions
radiation-induced lung injury (RILI)radiation pneumonitis (RP)radiation fibrosis syndrome (RIF)
Beyond the preview
Go deeper on NCT03796364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03796364.